Correlation of ENT Symptoms with Age, Sex, and Anti-SARS-CoV-2 Antibody Titer in Plasma

Our objective is to evaluate the correlation between ENT symptom occurrence and antibody titer in convalescent plasma, as well as the influence of age and gender on ENT manifestations of COVID-19. We measured the levels of antibodies in 346 blood donors, who had PCR-confirmed previous infection and met the study inclusion criteria. We recorded otolaryngological symptoms during infection: dry cough, dyspnea, sore throat, smell/taste disturbances, vertigo, dizziness, nausea and vomiting, sudden unilateral loss of hearing, progressive loss of hearing, and tinnitus. In addition, we statistically analyzed the correlation between patients’ antibody levels, symptoms, age, and gender using a chi-square test or Fisher exact test. A p-value less than 0.05 determined statistical significance. The mean age of the convalescents was 39.8 ± 9.56 SD and the median of the measured anti-SARS-CoV2 plasma antibodies was 1:368.5. The most common ENT symptoms were smell/taste disturbances (62.43%), dry cough (40.46%), sore throat (24.86%), and dyspnea (23.7%). Smell and taste disturbances were more frequent in younger patients and the marked antibody titer was lower, which was contrary to a higher antibody titer associated with dry cough, dyspnea, and dizziness. Occurrence of sore throat was not correlated with age, sex, or antibody level. There were no significant differences in otological symptoms in female patients. Gender does not affect the occurrence of ENT symptoms. The symptomatic course of SARS-CoV-2 infection is not always associated with higher levels of antibodies in the blood. The age of the infected patients, unlike gender, affects the occurrence of some ENT symptoms.

[1]  P. Bochud,et al.  Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19 , 2022, Viruses.

[2]  G. Lisowska,et al.  Frequency and Severity of Ear–Nose–Throat (ENT) Symptoms during COVID-19 Infection , 2022, Medicina.

[3]  R. Paton,et al.  Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers. , 2022, Danish medical journal.

[4]  K. Simon,et al.  Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022. , 2022, Polish archives of internal medicine.

[5]  H. Kunishima,et al.  Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID , 2022, Journal of medical virology.

[6]  W. Narożny,et al.  Assessment of anti‐SARS‐CoV‐2 antibodies level in convalescents plasma , 2021, Journal of medical virology.

[7]  A. Gözalan,et al.  Evaluation of antibody response after COVID‐19 vaccination of healthcare workers , 2021, Journal of medical virology.

[8]  Ying Shen,et al.  Serum Albumin Levels as a Potential Marker for the Predictive and Prognostic Factor in Sudden Sensorineural Hearing Loss: A Prospective Cohort Study , 2021, Frontiers in Neurology.

[9]  W. Mansour,et al.  Analysis of Ear, Nose and Throat Manifestations in COVID-19 Patients , 2021, International Archives of Otorhinolaryngology.

[10]  K. Simon,et al.  Management of SARS-CoV- infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. , 2021, Polish archives of internal medicine.

[11]  Qianghu Wang,et al.  Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19 , 2020, Nature Communications.

[12]  E. Hod,et al.  Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum , 2020, Nature Immunology.

[13]  M. Güven,et al.  Otolaryngological manifestations of hospitalised patients with confirmed COVID-19 infection , 2020, European Archives of Oto-Rhino-Laryngology.

[14]  Sin Young Ham,et al.  Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19 , 2020, The Korean journal of internal medicine.

[15]  E. Elibol Otolaryngological symptoms in COVID-19 , 2020, European Archives of Oto-Rhino-Laryngology.

[16]  S. Farhadian,et al.  Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.

[17]  Harnish Mukesh Naik,et al.  Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. , 2020, The Journal of clinical investigation.

[18]  M. Salesi,et al.  Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study , 2020, Transfusion and Apheresis Science.

[19]  Liyan Wen,et al.  Kinetics of viral load and antibody response in relation to COVID-19 severity. , 2020, The Journal of clinical investigation.

[20]  S. Elzayat,et al.  ENT manifestation in COVID-19 patients , 2020, Auris Nasus Larynx.

[21]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[22]  Hui Poh Goh,et al.  Treatment of COVID-19: old tricks for new challenges , 2020, Critical Care.

[23]  M. Fernández‐Reyes,et al.  Serum potassium concentrations: Importance of normokalaemia. , 2017 .

[24]  M. Heras,et al.  Serum potassium concentrations: Importance of normokalaemia. , 2017, Medicina clinica.

[25]  C. Ki,et al.  Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome , 2016, Annals of laboratory medicine.

[26]  J. Sung,et al.  Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.